SUDOSCAN检测快速有效评估硼替佐米致周围神经病变

陈绿云 殷佳慧 杨岚寓 杨光忠 耿传营 刘念 菅原 刘爱军

陈绿云, 殷佳慧, 杨岚寓, 杨光忠, 耿传营, 刘念, 菅原, 刘爱军. SUDOSCAN检测快速有效评估硼替佐米致周围神经病变[J]. 中国肿瘤临床, 2023, 50(8): 398-402. doi: 10.12354/j.issn.1000-8179.2023.20230066
引用本文: 陈绿云, 殷佳慧, 杨岚寓, 杨光忠, 耿传营, 刘念, 菅原, 刘爱军. SUDOSCAN检测快速有效评估硼替佐米致周围神经病变[J]. 中国肿瘤临床, 2023, 50(8): 398-402. doi: 10.12354/j.issn.1000-8179.2023.20230066
Lvyun Chen, Jiahui Yin, Lanyu Yang, Guangzhong Yang, Chuanying Geng, Nian Liu, Yuan Jian, Aijun Liu. SUDOSCAN: a tool for quick and effective evaluation of bortezomib-induced peripheral neuropathy[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(8): 398-402. doi: 10.12354/j.issn.1000-8179.2023.20230066
Citation: Lvyun Chen, Jiahui Yin, Lanyu Yang, Guangzhong Yang, Chuanying Geng, Nian Liu, Yuan Jian, Aijun Liu. SUDOSCAN: a tool for quick and effective evaluation of bortezomib-induced peripheral neuropathy[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(8): 398-402. doi: 10.12354/j.issn.1000-8179.2023.20230066

SUDOSCAN检测快速有效评估硼替佐米致周围神经病变

doi: 10.12354/j.issn.1000-8179.2023.20230066
详细信息
    作者简介:

    陈绿云:专业方向为多发性骨髓瘤的基础与临床研究

    通讯作者:

    刘爱军 aj0628@163.com

SUDOSCAN: a tool for quick and effective evaluation of bortezomib-induced peripheral neuropathy

More Information
  • 摘要:   目的  本研究旨在探索SUDOSCAN检测(一种外周自主神经功能检测工具)对硼替佐米致周围神经病变(bortezomib-induced peripheral neuropathy,BIPN)的评估效果。  方法  以2021年7月至2022年10月首都医科大学附属北京朝阳医院血液科确诊的86例多发性骨髓瘤(multiple myeloma,MM)患者作为研究对象,另外选取30例无肿瘤史及化疗药物接触史的患者作对照,所有患者均接受了SUDOSCAN皮肤电导率(ESC值)检测,同时与总神经病变评分临床版(TNSc)、美国国立癌症研究所常见毒性分级标准(NCI-CTC)分级评分对比,并对试验组患者进行了评估所需时间比较。  结果  试验组患者手部、足部ESC值比对照组明显降低(手部:56.4 μs vs. 76.5 μs,P<0.001;足部:47.5 μs vs. 78.0 μs,P<0.001);SODUSCAN 评估患者足部ESC值与TNSc评分呈显著负相关(r=−0.403,P<0.001)、与NCI-CTC等级无明显相关性(r=−0.227,P=0.051);NCI-CTC等级与TNSc评分呈显著正相关(r=0.591,P<0.001)。SUDOSCAN检测所需中位评估时间与NCI-CTC等级相近(均为2.4 min),TNSc评分所需中位评估时间最长(13.4 min)。  结论  目前,BIPN缺乏准确、高效评估方式,SUDOSCAN检测简单易行,与TNSc评分呈显著负相关,且比TNSc评分用时更短,能够快速有效评估BIPN。

     

  • 图  1  试验组与对照组手部、足部ESC值比较

    试验组:P=0.007;对照组:P=0.906

    表  1  试验组与对照组患者ESC值基本情况

    项目试验组(n=86)对照组(n=30)ZP
    SUDOSCAN检测结果
     0级21(24.4)30(100)
     1级29(33.7)
     2级36(41.9)
    手ESC值(μs)56.4(42.8~68.5)76.5(68.0~84.0)−5.506<0.001
    足ESC值(μs)47.5(22.0~66.0)78.0(69.0~81.3)−5.706<0.001
    ()内单位为%
    下载: 导出CSV

    表  2  试验组与对照组手部、足部ESC值比较

    组别指标ESC(μs)ZP
    试验组   手平均ESC值 vs. 足平均ESC值56.4(42.8~68.5) vs. 47.5(22.0~66.0)−2.7110.007
       左手ESC值 vs. 右手ESC值57.6(43.8~72.0) vs. 55.9(42.8~70.5)−0.4470.655
       左足ESC值 vs. 右足ESC值48.1(26.0~70.2) vs. 47.5(21.8~70.8)−0.1960.845
    对照组   手平均ESC值 vs. 足平均ESC值76.5(68.0~84.0) vs. 78.0(69.0~81.3)−0.1180.906
       左手ESC值 vs. 右手ESC值78.0(68.0~84.0) vs. 79.0(70.0~84.0)−0.3210.748
        左足ESC值 vs. 右足ESC值78.0(69.0~82.0) vs. 79.0(71.0~83.0)−0.7200.472
    下载: 导出CSV

    表  3  3种评估方式结果相关性分析

    项目rP
    NCI-CTC等级与TNSc0.591<0.001
    手ESC值与NCI-CTC等级−0.0450.704
    足ESC值与NCI-CTC等级−0.2270.051
    手ESC值与TNSc−0.2400.040
    足ESC值与TNSc−0.403<0.001
    下载: 导出CSV
  • [1] Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma[J]. Nat Rev Dis Primers, 2017, 3:17046. doi: 10.1038/nrdp.2017.46
    [2] Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature[J]. Blood, 2008, 112(5):1593-1599. doi: 10.1182/blood-2008-04-149385
    [3] Ludman T, Melemedjian OK. Bortezomib-induced aerobic glycolysis contributes to chemotherapy-induced painful peripheral neuropathy[J]. Mol Pain, 2019, 15:174-176.
    [4] 任咏惠,李丽,汪梅,等.硼替佐米致多发性骨髓瘤患者周围神经病变的研究进展[J].临床医学研究与实践,2022,7(4):196-198.
    [5] Li T, Timmins HC, King T, et al. Characteristics and risk factors of bortezomib induced peripheral neuropathy: a systematic review of phase Ⅲ trials[J]. Hematol Oncol, 2020, 38(3):229-243.
    [6] Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale[J]. Neurology, 2003, 61(9):1297-1300. doi: 10.1212/01.WNL.0000092015.03923.19
    [7] Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J]. J Natl Cancer Inst, 2014, 106(9):dju244. doi: 10.1093/jnci/dju244
    [8] Lavoie Smith EM, Cohen JA, Pett MA, et al. The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums[J]. Oncol Nurs Forum, 2011, 38(2):133-142.
    [9] Mao F, Liu SY, Qiao XN, et al. SUDOSCAN, an effective tool for screening chronic kidney disease in patients with type 2 diabetes[J]. Exp Ther Med, 2017, 14(2):1343-1350.
    [10] Mayaudon H, Miloche PO, Bauduceau B. A new simple method for assessing sudomotor function: relevance in type 2 diabetes[J]. Diabetes Metab, 2010, 36(6 Pt 1): 450-454.
    [11] Cavaletti G, Cornblath DR, Merkies ISJ, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings[J]. Ann Oncol, 2013, 24(2): 454-462.
    [12] Cavaletti G, Frigeni B, Lanzani F, et al. The total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale[J]. J Peripher Nerv Syst, 2007, 12(3):210-215. doi: 10.1111/j.1529-8027.2007.00141.x
    [13] San MJF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma[J]. N Engl J Med, 2008, 359(9):906-917. doi: 10.1056/NEJMoa0801479
    [14] Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial[J]. Lancet, 2017, 389(10068):519-527.
    [15] 杨光忠,陈文明.以硼替佐米为基础的联合方案治疗110例多发性骨髓瘤患者的疗效分析[J].中华医学杂志,2010,90(38):2671-2674. doi: 10.3760/cma.j.issn.0376-2491.2010.38.003
    [16] Reeve BB, McFatrich M, Mack JW, et al. Validity and reliability of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events[J]. J Natl Cancer Inst, 2020, 112(11):1143-1152. doi: 10.1093/jnci/djaa016
    [17] Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J]. JAMA Oncol, 2015, 1(8):1051-1059. doi: 10.1001/jamaoncol.2015.2639
    [18] 李杰,虎银凤,茹亚楠,等.化疗导致周围神经病变评估工具的研究进展[J].天津护理,2022,30(2):245-249. doi: 10.3969/j.issn.1006-9143.2022.02.033
    [19] Frigeni B, Piatti M, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale[J]. J Peripher Nerv Syst, 2011, 16(3):228-236. doi: 10.1111/j.1529-8027.2011.00351.x
    [20] 李旭宁,张如旭.周围神经病评分量表的研究进展[J].中国康复医学杂志,2013,28(4):381-385. doi: 10.3969/j.issn.1001-1242.2013.04.026
    [21] Casellini CM, Parson HK, Richardson MS, et al. Sudoscan, a noninvasive tool for detecting diabetic small fiber neuropathy and autonomic dysfunction[J]. Diabetes Technol Ther, 2013, 15(11):948-953. doi: 10.1089/dia.2013.0129
    [22] Saad M, Psimaras D, Tafani C, et al. Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy[J]. J Neurooncol, 2016, 127(2):373-380. doi: 10.1007/s11060-015-2049-x
  • 加载中
图(1) / 表(3)
计量
  • 文章访问数:  91
  • HTML全文浏览量:  16
  • PDF下载量:  31
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-01-29
  • 录用日期:  2023-02-27
  • 修回日期:  2023-02-21
  • 网络出版日期:  2023-03-08

目录

    /

    返回文章
    返回